Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Experimental RNAi

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...

RNA Interference

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

RNA Interference

RNA Interference

RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...

siRNA - Small Interfering RNAs

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...

Small interfering RNAs (siRNA)

Small interfering RNAs (siRNA)

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab.

Gut·2017

Same author

Assessment of global longitudinal strain at low-dose anthracycline-based chemotherapy for the prediction of subsequent cardiotoxicity.

Annales de cardiologie et d'angeiologie·2016

Same author

Sedation for transfemoral aortic valve transplantation (TAVI).

Anaesthesia·2016

Same author

Diagnosis of Cutaneous T-Cell Lymphoma Detecting T-Cell Receptor γ Chain Gene Monoclonality By Denaturing Gradient Gel Electrophoresis.

Acta clinica Belgica·2016

Same author

European evidence-based (S3) guideline for the treatment of acne - update 2016 - short version.

Journal of the European Academy of Dermatology and Venereology : JEADV·2016

Same author

Quality of life and patient benefit following transition from methotrexate to ustekinumab in psoriasis.

Journal of the European Academy of Dermatology and Venereology : JEADV·2016

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Published on: June 21, 2013

Cutaneous short-interfering RNA therapy.

B Geusens¹, N Sanders, T Prow

¹Ghent University Hospital, Department of Dermatology, De Pintelaan 185, B-9000 Ghent, Belgium. Barbara.Geusens@ugent.be

Expert Opinion on Drug Delivery

|November 28, 2009

Summary

This summary is machine-generated.

RNA interference (RNAi) therapy shows promise for gene-related skin disorders using short-interfering RNAs (siRNAs). Current delivery methods face challenges for widespread clinical use and patient compliance.

More Related Videos

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

Related Experiment Videos

Last Updated: Jun 18, 2026

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Long-term Silencing of Intersectin-1s in Mouse Lungs by Repeated Delivery of a Specific siRNA via Cationic Liposomes. Evaluation of Knockdown Effects by Electron Microscopy

Published on: June 21, 2013

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

Area of Science:

Molecular Biology
Genetics
Dermatology

Background:

RNA interference (RNAi) has evolved from a research tool to a therapeutic strategy for genetic diseases.
Short-interfering RNAs (siRNAs) enable sequence-specific gene silencing for therapeutic applications.
Growing interest exists in cutaneous delivery of siRNA for treating skin disorders.

Purpose of the Study:

To review the current findings and applications of cutaneous RNAi therapy.
To evaluate the potential and limitations of siRNA delivery systems for skin conditions.
To highlight challenges in translating cutaneous RNAi delivery to clinical practice.

Main Methods:

Literature review of preclinical and clinical studies on cutaneous siRNA delivery.
Analysis of various siRNA delivery techniques for dermatological applications.
Assessment of patient compliance factors for therapeutic RNAi.

Main Results:

Successful preclinical studies demonstrate the feasibility of cutaneous siRNA delivery.
Several delivery techniques show promise but face hurdles for clinical translation.
Patient compliance remains a significant consideration for effective therapeutic siRNA application in skin disorders.

Conclusions:

Cutaneous RNAi therapy holds significant potential for treating various skin diseases.
Delivery system optimization is crucial for overcoming clinical translation barriers.
Further research is needed to improve patient compliance and therapeutic efficacy of siRNA delivery for skin conditions.